Opponents Seek Stay on Cannabis Rescheduling Over Costs and Abuse Concerns

A drug-testing industry group (NDASA) and MMJ International Holdings urge a DC court to pause the government’s move to reschedule cannabis from Schedule I to Schedule III, arguing the change would raise drug-testing costs, create liability risks, and potentially increase marijuana abuse; they contend the challengers have standing and that the rulemaking was improper, as three consolidated lawsuits proceed and a DEA hearing continues, while opponents warn the policy would harm public safety and the industry’s ability to operate.